Teleflex Incorporated
$161.58-$1.82 (-1.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $5.8B
- P/E
- -6.5x
- EV / EBITDA
- 27.1x
- Revenue
- $2.0B
- Net margin
- -45.4%
- ROCE
- 4.1%
Price chart
Technical chartScreen technicals →+54.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +23.2%
- 3M
- +19.7%
- 6M
- +19.5%
- 1Y
- +54.4%
- 5Y
- -49.3%
52-week range
Day change -$1.82 (-1.1%) from $163 to $162 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in TFX, bought on each weekday since 2021.
News & filings
What Teleflex Incorporated filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 906 million US dollars in fiscal 2025.
Strengths (1)
- The price is 25.3% above its 200-day average, and the 50-day average is above the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Read moreShow less
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 44.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $5.8B
- P/E
- -6.5x
- P/B
- 1.9x
- EV / EBITDA
- 27.1x
- EV / Sales
- 4.1x
- P/S
- 2.9x
- 52-week high
- $165.85
- 52-week low
- $100.34
Profitability
- Operating margin
- 12.8%
- Net margin
- -45.4%
- EBITDA margin
- 15.2%
- ROE
- -29.0%
- ROCE
- 4.1%
- ROA
- -13.0%
- Asset turnover
- 0.29
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $2.0B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 17.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -10.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1399.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $245.4M
Solvency
- Current ratio
- 2.54
- Debt / Equity
- 0.87
- Debt / Assets
- 0.39
- CFO / Net profit
- -0.38
- Cash / Market cap
- 6.5%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $2.0B |
| Cost of revenue | $872.0M |
| Gross profit | $1.1B |
| Operating expenses | $865.0M |
| Research and development | $144.8M |
| Selling, general and administrative | $720.2M |
| Operating income | $255.8M |
| Interest and other | -$231.3M |
| Pretax income | $24.6M |
| Tax and other | $930.2M |
| Net income | -$905.6M |
Revenue and net profit
Revenue grew 17.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.8B | $363.1M |
| FY2023 | $1.7B | $356.3M |
| FY2024 | $1.7B | $69.7M |
| FY2025 | $2.0B | -$905.6M |
Cash flows
FY2025: $340.7M from operations, $245.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $342.1M | $263.0M |
| FY2023 | $510.6M | $464.2M |
| FY2024 | $635.7M | $545.3M |
| FY2025 | $340.7M | $245.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $2.0B+17.2%1Y
- EBITDA
- $302.5M+11.5%1Y
- Net profit
- -$905.6M-1,399.8%1Y
- Cash from operations
- $340.7M-46.4%1Y
- Free cash flow
- $245.4M-55.0%1Y
- Revenue CAGR, 3Y
- -10.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.0B | $302.5M | -$905.6M | $245.4M | -29.0% | +17.2% | -1399.8% |
Monthly returns
Month-by-month returns of TFX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $6.9B |
| Current assets | $1.9B |
| Non-current assets | $5.0B |
| Liabilities | $3.8B |
| Current liabilities | $762.0M |
| Non-current liabilities | $3.1B |
| Equity | $3.1B |
| Paid-in capital | $815.8M |
| Retained earnings | $3.1B |
| Treasury stock | $649.5M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; TFX highlighted.
P/E against peers
TFX has no positive P/E; the peer median is 17.5x.
Not shown (no positive earnings and no EV / Sales): Teleflex Incorporated, Glaukos Corporation, Protagonist Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Teleflex IncorporatedTFXthis company | $5.8B | -6.5x | 1.9x | -29.0% | 27.1x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Protagonist Therapeutics, Inc.PTGX | $6.6B | -50.8x | 10.8x | -21.2% | -41.4x |
| TG Therapeutics, Inc.TGTX | $6.2B | 13.9x | 9.6x | 69.0% | 47.5x |
| PTC Therapeutics, Inc.PTCT | $5.9B | 8.6x | — | -332.5% | 7.5x |
| Apellis Pharmaceuticals, Inc.APLS | $5.3B | 234.6x | 14.2x | 6.0% | 75.2x |
| Ligand Pharmaceuticals IncorporatedLGND | $4.7B | 38.0x | 4.6x | 12.2% | 25.3x |
| Indivior Pharmaceuticals, Inc.INDV | $4.4B | 21.1x | -44.7x | -212.1% | 15.1x |
| Peer median | — | 17.5x | 9.6x | -7.6% | 18.0x |
Year-to-date ROI
TFX since 1 January, against earlier years.
Historical volatility
TFX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 18.4% |
| FY2023 | 17.7% |
| FY2024 | 14.9% |
| FY2025 | 12.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $2.0B |
| Cost of revenueCost Of Revenue | $872.0M |
| Gross profitGross Profit | $1.1B |
| Operating expensesOperating Expense | $865.0M |
| Research and developmentResearch And Development | $144.8M |
| Selling, general and administrativeSelling General And Administration | $720.2M |
| Total expensesTotal Expenses | $1.7B |
| Operating incomeOperating Income | $255.8M |
| Interest and other | |
| Pretax incomePretax Income | $24.6M |
| TaxTax Provision | -$34.0M |
| Net incomeNet Income | -$905.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $6.9B |
| Current assetsCurrent Assets | $1.9B |
| Non-current assetsTotal Non Current Assets | $5.0B |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.8B |
| Current liabilitiesCurrent Liabilities | $762.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $3.1B |
| EquityTotal Equity Gross Minority Interest | $3.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $340.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $96.7M |
| Net income, continuing operationsNet Income From Continuing Operations | -$905.6M |
| Depreciation and amortisationDepreciation And Amortization | $177.7M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $177.7M |
| Depreciation | $56.1M |
| Amortization cash flowAmortization Cash Flow | $121.7M |
| Amortization of intangiblesAmortization Of Intangibles | $121.7M |
| Stock-based compensationStock Based Compensation | $25.7M |
| Deferred taxDeferred Tax | -$101.0M |
| Deferred income taxDeferred Income Tax | -$101.0M |
| Operating gains and lossesOperating Gains Losses | -$82.6M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$82.6M |
| Asset impairmentAsset Impairment Charge | $108.1M |
| Pension and employee benefit expensePension And Employee Benefit Expense | $0.00 |
| Change in working capitalChange In Working Capital | -$45.4M |
| Other non-cash itemsOther Non Cash Items | $955.5M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | $244.0M |
| Investing cash flowInvesting Cash Flow | -$849.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$812.6M |
| Capital expenditureCapital Expenditure | -$95.2M |
| Capital expenditure (reported)Capital Expenditure Reported | -$95.2M |
| AcquisitionsPurchase Of Business | -$831.9M |
| DisposalsSale Of Business | $6.7M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$825.1M |
| Purchase of investmentsPurchase Of Investment | -$5.0M |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | -$5.0M |
| Interest received (investing)Interest Received Cfi | $21.1M |
| Other investing changesNet Other Investing Changes | $91.7M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | -$36.5M |
| Financing cash flowFinancing Cash Flow | $611.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $611.5M |
| Debt issuedIssuance Of Debt | $1.1B |
| Debt repaidRepayment Of Debt | -$153.0M |
| Net debt issuedNet Issuance Payments Of Debt | $987.0M |
| Long-term debt issuedLong Term Debt Issuance | $1.1B |
| Long-term debt repaidLong Term Debt Payments | -$153.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $987.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$300.0M |
| Common stock repurchasedCommon Stock Payments | -$300.0M |
| Share buybacksRepurchase Of Capital Stock | -$300.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $7.2M |
| Dividends paidCash Dividends Paid | -$60.3M |
| Common dividends paidCommon Stock Dividend Paid | — |
| Other financing chargesNet Other Financing Charges | -$22.4M |
| Change in cashChanges In Cash | $103.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2,317.0% |
| Other cash adjustment outside change in cashOther Cash Adjustment Outside Changein Cash | -$51.2M |
| Cash at the start of the yearBeginning Cash Position | $327.6M |
| Cash at the end of the yearEnd Cash Position | $402.7M |
| Free cash flowFree Cash Flow | $245.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Teleflex Incorporated and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read